KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 1,706 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $13,016.78. Following the completion of the sale, the chief financial officer now directly owns 68,581 shares in the company, valued at $523,273.03. This represents a 2.43 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

KALA BIO Trading Down 11.3 %

Shares of NASDAQ:KALA opened at $6.82 on Friday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. The stock has a market capitalization of $31.44 million, a price-to-earnings ratio of -0.55 and a beta of -2.11. KALA BIO, Inc. has a 1-year low of $4.21 and a 1-year high of $9.25. The company has a 50 day moving average price of $6.70 and a 200 day moving average price of $6.33.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping the consensus estimate of ($2.43) by $0.50. On average, research analysts anticipate that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of KALA BIO in a report on Friday, November 15th.

Hedge Funds Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP bought a new position in KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for approximately 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th biggest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent quarter. 24.61% of the stock is owned by institutional investors.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.